En bloc resection and prosthesis implantation to treat malignant fibrous histiocytoma of the humerus

Sun, Jun Zhong; Zhang, Ruming; Zheng, Yuxin

doi:10.17219/acem/63744

Cited by 3 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Malignant fibrous histiocytoma (MFH), also known as undifferentiated pleomorphic sarcoma (UPS), is a pleomorphic tumor consisting of fibroblasts, myofibroblasts, and histiocytes, which is initially identified as a histologically distinctive type of sarcoma in 1964 [1,2]. Since the characteristics of MFH were defined, this tumor has become the most common type of soft tissue tumor.…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological characteristics and survival of malignant fibrous histiocytoma of the bone: A population-based study using the SEER database

Liu¹,

Wei

Ren

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

Malignant fibrous histiocytoma of the bone (MFH-B) is an extremely rare and aggressive malignancy. The clinicopathological characteristics and prognosis of patients with MFH-B have not been defined. We conducted a retrospective study using the data of all MFH-B patients from the Surveillance, Epidemiology and End Results (SEER) database between 1975 and 2016. Initially, the clinicopathological characteristics were described. The difference in prognosis between patients with MFH-B and those with osteosarcoma was compared using propensity score matching analysis. Then, the features affecting the prognosis of patients with MFH-B were further determined using Cox regression analysis. A total of 318 patients with MFH-B were identified. The median overall survival (mOS) of all 318 patients with MFH-B was 29.0 months. The 1-, 3-, 5-, and 10-year survival rates were 67.4%, 53.6%, 38.7%, and 28.7%, respectively. The multivariate Cox regression analysis showed that older age, distant metastases, and flat bone lesion were independent factors for worse prognosis, whereas surgery was an independent factor for favorable survival, and this intervention could decrease risk of death by 61% (HR = 0.39, 95% CI 0.28-0.54). Apart from this, the prognosis of patients with MFH-B was significantly worse than that of patients with osteosarcoma in both unmatched and matched cohorts. In conclusion, MFH-B is a rare malignant bone cancer, with relatively worse prognosis than osteosarcoma. Older age, distant metastases, flat bone lesion, and surgery were independently associated with prognosis. In order to understand this disease more thoroughly and accurately, more cases with adequate information are required in the future.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinicopathological characteristics and survival of malignant fibrous histiocytoma of the bone: A population-based study using the SEER database

Liu¹,

Wei

Ren

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

show abstract

Upfront surgical resection for primary bone tumors: rationale and potential benefits

et al. 2020

View full text Add to dashboard Cite

Local control for the treatment of primary bone tumors is generally delayed following neoadjuvant chemotherapy. This was born out of the historical need to manufacture custom implants when performing limb-salvage resection. There is increasing reason to reconsider the timing of local control in the setting of primary bone tumors. In this report, we describe two cases in which upfront surgery was utilized and review rationale, prior literature, and potential benefits of this approach.

show abstract

Antiproliferative effect of bupivacaine on patient-derived sarcoma cells

et al. 2020

View full text Add to dashboard Cite

Sarcomas are rare tumors with limited treatment options. Although chemotherapy is standard for certain subtypes, overall survival has not improved in several decades. Bupivacaine has been shown to induce apoptosis and prevent cell growth in multiple different types of malignancies but has not been studied in sarcoma. The current study evaluated the effects of bupivacaine on multiple patient-derived sarcoma cells and a commercial sarcoma cell line. Multiple patient-derived sarcoma cell subtypes and a commercial synovial cell sarcoma cell line were exposed to bupivacaine for different durations and at different concentrations. The patient-derived cells included a high-grade conventional osteosarcoma, a high-grade undifferentiated pleomorphic sarcoma of bone, and a high-grade synovial sarcoma. Flow cytometry and an MTT assay were used to evaluate whether a treatment effect was observed. Treatment of all the subtypes of sarcomas in this study with bupivacaine demonstrated a time- and dose-dependent increase in apoptosis and decrease in cell viability. A cell viability assay demonstrated that the IC 50 was between 0.04 and 0.05% and that the treatment effect occurred at clinically relevant doses in vitro . Bupivacaine was toxic to both the patient-derived cells and the commercial cell line at doses commonly used in the clinical setting. These findings provide a foundation for further in vivo studies to evaluate whether these effects will translate to the clinical setting. Although further research is necessary, bupivacaine shows promise as not only an adjunct for pain management but as a treatment modality for sarcoma.

show abstract

En bloc resection and prosthesis implantation to treat malignant fibrous histiocytoma of the humerus

Cited by 3 publications

References 32 publications

Clinicopathological characteristics and survival of malignant fibrous histiocytoma of the bone: A population-based study using the SEER database

Clinicopathological characteristics and survival of malignant fibrous histiocytoma of the bone: A population-based study using the SEER database

Upfront surgical resection for primary bone tumors: rationale and potential benefits

Antiproliferative effect of bupivacaine on patient-derived sarcoma cells

Contact Info

Product

Resources

About

En bloc resection and prosthesis implantation to treat malignant fibrous histiocytoma of the humerus

Cited by 3 publications

References 32 publications

Clinicopathological characteristics and survival of malignant fibrous histiocytoma of the bone: A population-based study using the SEER database

Clinicopathological characteristics and survival of malignant fibrous histiocytoma of the bone: A population-based study using the SEER database

Upfront surgical resection for primary bone tumors: rationale and potential benefits

Antiproliferative effect of bupivacaine on&nbsp;patient-derived sarcoma cells

Contact Info

Product

Resources

About

Antiproliferative effect of bupivacaine on patient-derived sarcoma cells